Lyell Immunopharma, Inc. (LYEL) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is neutral — 1 Buy, 3 Hold, 1 Sell.
The consensus price target is $45.00, representing an upside of 88.8% from the current price $23.84.
Analysts estimate Earnings Per Share (EPS) of $-14.60 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.31 vs est $-14.60 (beat +91%). 2025: actual $-16.06 vs est $-10.53 (missed -52.5%). Analyst accuracy: 0%.
LYEL Stock — 12-Month Price Forecast
$45.00
▲ +88.76% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Lyell Immunopharma, Inc., the price target is $45.00.
The average price target represents a +88.76% change from the last price of $23.84.
LYEL Analyst Ratings
Hold
Based on 5 analysts giving stock ratings to Lyell Immunopharma, Inc. in the past 3 months
EPS Estimates — LYEL
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.31
vs Est –$14.60
▲ 1,013.1% off
2025
Actual –$16.06
vs Est –$10.53
▼ 34.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — LYEL
90%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.000B
▲ 19.7% off
2025
Actual $0.000B
vs Est $0.000B
▼ 0.6% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
